Ren, Wenfeng http://orcid.org/0009-0001-8073-8720
Xu, Zilong http://orcid.org/0009-0001-5619-5834
Chang, Yating http://orcid.org/0009-0009-6536-8504
Ju, Fei
Wu, Hongning
Liang, Zhiqi
Zhao, Min
Wang, Naizhen
Lin, Yanhua
Xu, Chenhang
Chen, Shengming
Rao, Yipeng
Lin, Chaolong
Yang, Jianxin
Liu, Pingguo http://orcid.org/0000-0001-7177-7333
Zhang, Jun http://orcid.org/0000-0002-6601-9180
Huang, Chenghao http://orcid.org/0000-0001-8267-1307
Xia, Ningshao http://orcid.org/0000-0003-0179-5266
Funding for this research was provided by:
National Natural Science Foundation of China (81991491, 81991491)
Article History
Received: 25 January 2023
Accepted: 14 December 2023
First Online: 2 January 2024
Competing interests
: Xiamen University has filed a patent application covering ‘Application of OTUB2-targeted drugs and methods in cancer immunotherapy’ (No. 202310740647.7). C.H., W.R., Z.X., Y.C., M.Z., H.W., C.X., J.Z. and N.X. are listed as inventors. All other authors declare that they have no competing interests.